

COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination

by Hannah Stevens, Sergio Ruiz-Carmona, Karlheinz Peter, and James McFadyen

Received: October 11, 2022.

Accepted: January 17, 2023.

Citation: Hannah Stevens, Sergio Ruiz-Carmona, Karlheinz Peter, and James McFadyen. COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination. Haematologica. 2023 Jan 26. doi: 10.3324/haematol.2022.282262 [Epub ahead of print]

Publisher's Disclaimer.

E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.

**COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients,
following COVID-19 vaccination**

Short title: COVID-19 thromboembolism

Hannah Stevens^{*1,2,3}, Sergio Ruiz-Carmona^{*4}, Karlheinz Peter^{#3,5,6}, and James
McFadyen^{#1,2,3,6}

1. Department of Haematology, Alfred Hospital, Melbourne, Victoria, Australia 3004
2. Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
3. Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia 3004
4. Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Australia 3004
5. Department of Cardiology, Alfred Hospital, Melbourne, Australia 3004
6. Baker Department of Cardiometabolic Health, The University of Melbourne, Victoria, Australia 3010

*HS and SRC contributed equally as principal investigators

#KP and JM contributed equally as senior authors

Corresponding author:

Associate Professor James McFadyen

Atherothrombosis and Vascular Biology Program,

Baker Heart and Diabetes Institute,

75 Commercial Rd, PO Box 6492, Melbourne VIC 3004 Australia

Email: james.mcfadyen@monash.edu

Authorship

H.S. contributed to the study design, analysis and interpretation of data, drafting and revision of the manuscript.

S.R.C. contributed to the study design, acquisition and analysis of data, and drafting and revision of the manuscript.

J.D.M. contributed to the study design, interpretation of data, and drafting and revision of the manuscript.

K.P. contributed to the study design, interpretation of data, and drafting and revision of the manuscript.

Data sharing statement:

Data is available from researchers upon request.

Word count

Main text: 1438

Figure/tables: 2

References: 12

Acknowledgments

H. Stevens is supported by the Monash University Research Training Program Scholarship and Wheaton Family PhD Scholarship. K. Peter is supported by a National Health and Medical Research Council (NHMRC) L3 Investigator Research Fellowship. J.D. McFadyen is supported by a NHMRC and Heart Foundation Future Leader Fellowship.

Funding

None

Disclosures

None

The risk of venous thromboembolism (VTE) is increased in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is associated with higher mortality(1-3). Despite changes to thromboprophylaxis regimens in patients hospitalized with COVID-19, high rates of VTE have been reported in the second and third waves of COVID-19(1, 3). With widespread COVID-19 vaccine availability, whether vaccination influences the risk of COVID-19-associated thromboembolism (COVID-19 TE) in ambulatory and hospitalized patients remains an important question.

Here, we use data from the large United Kingdom (UK) Biobank and perform a cohort study to investigate the association between COVID-19 vaccination and COVID-19 TE. The UK Biobank is a prospective population-based study with comprehensive health and genetic data for over 500,000 participants who were recruited to the Biobank between 2006 and 2010(4). Data collection occurred from 1st February 2020 until 30 September 2021. We defined an early-pandemic, unvaccinated cohort (1st February 2020 to 31st December 2020) and compared to patients who received a first or second dose of any COVID-19 vaccination, between 1st January 2021 and 30th June 2021 (**Figure 1**). Patients were characterized by age, gender, body mass index and smoking status. Participants were excluded if demographic or health data was incomplete.

Patients were evaluated for the development of COVID-19 infection, defined by a positive SARS-CoV-2 test more than 14 days after COVID-19 vaccination. COVID-19 test result data was provided to UK Biobank by Public Health England, Public Health Scotland and Secure Anonymized Information Linkage for England, Scotland and Wales, respectively. Participants were defined as hospitalized, if the SARS-CoV-2 test was ordered as a hospital inpatient (which includes Accident and Emergency, hospital ward inpatients and patients in

Intensive Care Units), or if the test was flagged as a hospital acquired infection. Ambulatory participants were defined as anyone receiving a positive SARS-CoV-2 test that did not meet the criteria for hospitalization.

COVID-19 TE was defined as an International Classification of Diseases (ICD)-10 code for deep vein thrombosis (i.e., I801, I802, and I822) or pulmonary embolism (i.e., I260 and I269) occurring within 90 days of COVID-19 infection.

Statistical analysis was performed using R version 4.0.3. Data is available from researchers upon request. We performed logistic regression and calculated odds ratios (OR) with 95% confidence intervals for the outcome of COVID-19 TE, adjusted by the variables of age, gender and body mass index.

The UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee (11/NW/0382). All participants gave written informed consent. This research has been conducted using the UK Biobank Resource under application number 55469.

Overall, 218,915 individuals were included in the analysis, with 152,401 individuals in the early-pandemic unvaccinated cohort, 39,495 individuals in the first dose cohort, and 27,019 individuals in the second dose cohort. Demographic information is shown in **Table 1**. Within the unvaccinated cohort, COVID-19 was diagnosed in 13,028 patients (8.5%), compared with 3,593 (9.1%) individuals following first dose of COVID-19 vaccination, and 1,904 (7.0%) individuals following the second dose of vaccination (**Table 1**).

COVID-19 infection resulting in hospitalization occurred in 2703 (20.7%) of the unvaccinated cohort, 54 (1.5%) of the first dose cohort and 39 (2%) patients of the second dose cohort. Death from COVID-19 occurred in 1.1% of the unvaccinated cohort, and 0.1% patients of both the first and second dose cohorts (**Table 1**).

The incidence of COVID-19 TE in the unvaccinated cohort was 1.4%, which decreased to 0.2% following the first dose of COVID-19 vaccination (OR 0.18, 95% CI 0.09-0.36, $p < 0.001$) and to 0.1% after the second dose of vaccination (OR 0.06, 95% CI 0.02-0.26, $p < 0.001$) (**Table 1**). Across the three cohorts, PE rather than DVT was the predominant type of venous thrombotic event diagnosed, and accounted for 80.1%, 87.5% and 100% of all events in the unvaccinated, first dose and second dose cohorts, respectively. Despite the marked reduction in overall COVID-19 TE, the incidence of COVID-19 TE in hospitalized patients remained elevated. In the unvaccinated cohort, the incidence of COVID-19 TE following hospitalization for COVID-19 infection was 163/2,703 (6%), compared with 6/54 (11.1%) in the first dose cohort and 2/39 (5.1%) in the second dose cohort. By contrast, COVID-19 TE rates in ambulatory patients remained low across all cohorts, being diagnosed in 0.2% of the unvaccinated cohort, 0.1% of the first dose cohort, with no events diagnosed in the second dose cohort (**Table 1**).

Our study demonstrates a marked reduction in the rate of COVID-19 TE following one or two doses of COVID-19 vaccination compared to an unvaccinated cohort. However, this reduction in COVID-19 TE appears to be largely driven by a reduction in severe COVID-19 infection requiring hospitalization. Indeed, although the number of patients requiring hospitalization for COVID-19 was markedly reduced, the incidence of COVID-19 TE in

hospitalized patients remained relatively stable and was diagnosed in 6% of the early pandemic cohort, 11.1% of the first dose cohort and 5.1% of the second dose cohort. Conversely, we demonstrate that the incidence of COVID-19 TE in the first 90 days after COVID-19 infection in ambulatory patients is low.

To our knowledge, this is the first study to evaluate COVID-19 TE in vaccinated individuals in both ambulatory and hospitalized patients. Recently, Xie and colleagues demonstrated that COVID-19 vaccination attenuates the risk of COVID-19 TE in the first 30 days following infection in ambulatory patients, but no hospitalized individuals were included(5). Our study, which evaluated patients until 90 days post COVID-19 infection, supports that COVID-19 vaccination is associated with a reduced risk of COVID-19 TE, which appears to be predominantly due the lower rate of hospitalization with COVID-19 infection. These findings also support the recently published randomized clinical trials evaluating the use of thromboprophylaxis in outpatients with COVID-19, that demonstrated low rates of VTE regardless of thromboprophylaxis or vaccination status(6, 7).

Whether COVID-19 vaccination mitigates the risk of COVID-19 TE in hospitalized patients remains to be fully elucidated. Although the majority of VTE events in our study across all cohorts were diagnosed in patients who were hospitalized for COVID-19 infection, the absolute event rate was low due to a reduction in severe COVID-19 infection. Currently, several international professional society guidelines recommend therapeutic anticoagulation for non-ICU patients hospitalized with COVID-19 acute illness to prevent major thromboembolism and reduce mortality(8, 9). Our results suggest that patients hospitalized with COVID-19 have an elevated risk of VTE independent of vaccination status, and thus are

supportive of these guidelines. However, it will be important to prospectively validate the benefit of such anticoagulant strategies in populations with high vaccine coverage.

The strengths of this study include the large study size with access to free universal healthcare through the UK National Health Service, increasing the likelihood that COVID-19 therapies were consistent between cohorts. Limitations include the lack of available data regarding vaccination type, COVID-19 specific therapeutics and anticoagulation regimens prescribed to COVID-19 cases and. Due to the retrospective nature of the study and the use of ICD-10 codes, the study did not capture several patient factors, such as medical comorbidities and current medical therapies, or further information regarding VTE, which includes the type of diagnostic imaging used for VTE, the specific location of DVT, or whether the events were symptomatic in nature. Moreover, our definition of hospitalization for COVID-19 may include cases where COVID-19 was an incidental finding on routine hospital testing, and not the cause for hospitalization. Whether vaccine-induced immune thrombotic thrombocytopenia (VITT) or other vaccine-related thrombotic events were captured in the vaccinated population in this study is not known. However, the mean time from COVID-19 vaccination to COVID-19 infection was 176.4 days and 140.8 days in the first and second dose cohorts, respectively, and COVID-19 TE was diagnosed up to 90 days post infection. Given that VITT is extremely rare (reported incidence ranging from 1 in 26,000 to 2.1 in 100,000 individuals following one dose of ChAdOx1 nCov-19 [AstraZeneca, Sydney, NSW, Australia]), and vaccine-related thrombotic events and VITT typically present within 30 days of vaccination, the likelihood of capturing these events is extremely low(10-12). Finally, the inclusion of a contemporaneous unvaccinated cohort is unable to be included due to the high vaccine coverage in the UK.

In summary, these findings demonstrate that the rate of COVID-19 TE is low in a large population with high vaccination rates and access to COVID-19 therapeutics. Moreover, this reduction in COVID-19 TE appears to be driven by significantly lower rates of hospitalization with COVID-19 infection. Our findings suggest that the rate of COVID-19 TE is very low in ambulatory patients, but that the risk of COVID-19 TE persists in individuals requiring hospitalization with COVID-19, regardless of vaccination status. Further clinical trials should address optimal anticoagulation strategies in the era of widespread COVID-19 vaccination.

References

1. Katsoularis I, Fonseca-Rodriguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. *BMJ*. 2022;377:e069590.
2. McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. *Circ Res*. 2020;127(4):571-587.
3. Dutch Covid Thrombosis Coalition, Kaptein FHJ, Stals MAM, et al. Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. *Thromb Res*. 2021;199:143-148.
4. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562(7726):203-209.
5. Xie J, Prats-Urbe A, Feng Q, et al. Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19. *JAMA Intern Med*. 2022;182(10):1063-1070.
6. Cools F, Virdone S, Sawhney J, et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. *Lancet Haematol*. 2022;9(8):e594-e604.
7. Barco S, Voci D, Held U, et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet Haematol*. 2022;9(8):e585-e593.
8. Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. *JAMA Intern Med*. 2021;181(12):1612-1620.
9. REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *N Engl J Med*. 2021;385(9):777-789.
10. Dix C, McFadyen J, Huang A, Chunilal S, Chen V, Tran H. Understanding vaccine-induced thrombotic thrombocytopenia (VITT). *Intern Med J*. 2022;52(5):717-723.
11. Greinacher A, Langer F, Makris M, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. *J Thromb Haemost*. 2022;20(1):149-156.
12. Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. *BMJ*. 2021;374:n1931.

Table 1: Study cohort clinical characteristics and results

	Unvaccinated	Vaccinated	
		First dose	Second dose
Total study participants, No.	152,401	39,495	27,019
Individuals diagnosed with COVID-19, No. (%)	13,028 (8.5)	3,593 (9.1)	1,904 (7.0)
Age, mean (SD)	65.1 (\pm 8.6)	63.8 (\pm 7.8)	67.4 (\pm 7.5)
Female sex, No. (%)	80,010 (52.5)	21,011 (53.2)	14,887 (55.1)
BMI (kg/m²) \geq30 (%)	46,482 (30.5)	8,886 (22.5)	6,971 (25.8)
Current/previous smoker, No. (%)	72,390 (47.5)	16,943 (42.9)	12,267 (45.4)
COVID-19 infection details			
<i>Mean time to from vaccination to infection, days (SD)</i>		176.4 (\pm 56.7)	140.8 (\pm 45.3)
<i>Hospitalization status, No. (%)</i>			
<i>Hospitalized</i>	2,703 (20.7)	54 (1.5)	39 (2)
<i>Ambulatory</i>	10,325 (79.3)	3,539 (98.5)	1,865 (98)
<i>Death from COVID-19, No. (%)</i>	143 (1.1)	2 (0.1)	2 (0.1)
Venous thromboembolism			
<i>COVID-19 TE (all patients), No. (%)</i>	186 (1.4)	8 (0.2)	2 (0.1)
<i>Pulmonary embolism</i>	149/186 (80.1)	7/8 (87.5)	2/2 (100)
<i>Deep vein thrombosis</i>	37/186 (19.9)	1 (12.5)	0
<i>COVID-19 TE by hospitalization status for COVID-19 infection</i>			
<i>Hospitalized</i>	163/2703 (6)	6/54 (11.1)	2/39 (5.1)
<i>Ambulatory</i>	23/10,325 (0.2)	2/3,539 (0.1)	0/1865

<i>OR* for COVID-19 TE (all patients), (95% CI)</i>	Reference	0.18 (0.09 – 0.36, p<0.001)	0.06 (0.02 – 0.26, p<0.001)
---	-----------	--------------------------------	--------------------------------

*Odds ratio adjusted by age, gender and body mass index

Abbreviations: BMI, body mass index; CI, confidence interval; COVID-19, coronavirus disease 2019; COVID-19 TE, COVID-19-associated thromboembolism; OR, odds ratio; SD, standard deviation

Figure legend

Figure 1: Study design

Created with BioRender.com

Abbreviations: COVID-19, coronavirus disease 2019; VTE, venous thromboembolism



Population

Adult patients aged 45-69 at enrollment to UK Biobank

